Asia L/S Equity PM/Macro/Thematic Idea Generation

Rikki Malik

Cross Asset Strategy

<ul>
<li>A monthly review of how the markets and our themes are currently performing</li>
<li>Analysing what went wrong and what went right in stocks and sectors</li>
<li>Highlighting positions added or removed from the thematic investment portfolio</li>
</ul>


A monthly review of how the markets and our themes are currently performing
Analysing what went wrong and what went right in stocks and sectors
Highlighting positions added or removed from the thematic investment portfolio


April Themes and Thematic Portfolio Review

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

AdvisorShares Pure US Cannabis ETF / Equity Bottom-Up

AdvisorShares Pure US Cannabis ETF (MSOS US)

<ul>
  <li>The <a href="https://smartkarma.com/entities/advisorshares-pure-us-cannabis-etf">AdvisorShares Pure US Cannabis ETF</a> (MSOS) offers targeted exposure to the U.S. cannabis market, a sector with significant growth potential contingent on regulatory reform.</li>
  <li>The ETF is actively managed and highly concentrated in a few large multi-state operators (MSOs), making it a high-risk, high-reward investment vehicle sensitive to both company-specific news and broader industry catalysts.</li>
  <li>The primary driver for MSOS's future performance is the potential for U.S. federal cannabis reform, particularly the rescheduling of cannabis, which would alleviate significant tax burdens (IRC Section 280E) and improve access to banking services for the underlying companies.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  The AdvisorShares Pure US Cannabis ETF (MSOS) offers targeted exposure to the U.S. cannabis market, a sector with significant growth potential contingent on regulatory reform.
  The ETF is actively managed and highly concentrated in a few large multi-state operators (MSOs), making it a high-risk, high-reward investment vehicle sensitive to both company-specific news and broader industry catalysts.
  The primary driver for MSOS's future performance is the potential for U.S. federal cannabis reform, particularly the rescheduling of cannabis, which would alleviate significant tax burdens (IRC Section 280E) and improve access to banking services for the underlying companies.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: AdvisorShares Pure US Cannabis ETF (MSOS US) - Apr 2026

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>Rescheduling Is the Single Biggest Catalyst for US Cannabis.</li><li>It removes the 280E tax burden that prevents US plant-touching operators from deducting ordinary operating expenses, which in many cases doubles the effective tax rate.</li><li>280E only applies to Schedule I and II drugs, so the proposed move to Schedule III would remove 280E.</li></ul>

Rescheduling Is the Single Biggest Catalyst for US Cannabis.It removes the 280E tax burden that prevents US plant-touching operators from deducting ordinary operating expenses, which in many cases doubles the effective tax rate.280E only applies to Schedule I and II drugs, so the proposed move to Schedule III would remove 280E.

WTR Small-Cap Spotlight Recap - Five Cannabis Trends for 2025

November Themes and Thematic Portfolio Review

<ul><li>For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA for its MDMA-AT candidate for PTSD.</li><li>The FDA’s decision flew in the face of the anticipatory excitement following the NDA submission and award of breakthrough therapy designation earlier in the year following impressive results from Lykos’ two- part Phase 3 trial.</li><li>However, as disappointing as it is, particularly for the many millions of PTSD sufferers and Lykos, which subsequently reduced its workforce by 75%, in the grand scheme of things, this is only a temporary setback.</li></ul>

For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA for its MDMA-AT candidate for PTSD.The FDA’s decision flew in the face of the anticipatory excitement following the NDA submission and award of breakthrough therapy designation earlier in the year following impressive results from Lykos’ two- part Phase 3 trial.However, as disappointing as it is, particularly for the many millions of PTSD sufferers and Lykos, which subsequently reduced its workforce by 75%, in the grand scheme of things, this is only a temporary setback.

Shroom Shmooz Psychedelics: Trends to Watch Going into 2025

United States

The AdvisorShares Pure US Cannabis ETF is an actively managed exchange-traded fund incorporated in the USA.  The fund seeks to seeks long-term capital appreciation by investing in the US Cannabis industry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AdvisorShares Pure US Cannabis ETF (MSOS US)

April Themes and Thematic Portfolio Review

We review overall market performance, our investment themes, highlighting additions and substractions in the thematic portfolio.

Rikki Malik

Primer: AdvisorShares Pure US Cannabis ETF (MSOS US) - Apr 2026

The AdvisorShares Pure US Cannabis ETF (MSOS) offers targeted exposure to the U.S. cannabis market, a sector with significant growth potential...

αSK Primers

WTR Small-Cap Spotlight Recap - Five Cannabis Trends for 2025

Rescheduling Is the Single Biggest Catalyst for US Cannabis. It removes the 280E tax burden that prevents US plant-touching operators from...

Water Tower Research

November Themes and Thematic Portfolio Review

We review overall market performance, our investment themes, highlighting additions and substractions in the thematic portfolio.

Rikki Malik

Shroom Shmooz Psychedelics: Trends to Watch Going into 2025

For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)